153 related articles for article (PubMed ID: 29921201)
1. Characterization CYP1A2, CYP2C9, CYP2C19 and CYP2D6 Polymorphisms Using HRMA in Psychiatry Patients with Schizophrenia and Bipolar Disease for Personalized Medicine.
Yenilmez ED; Tamam L; Karaytug O; Tuli A
Comb Chem High Throughput Screen; 2018; 21(5):374-380. PubMed ID: 29921201
[TBL] [Abstract][Full Text] [Related]
2. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
[TBL] [Abstract][Full Text] [Related]
3. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
[TBL] [Abstract][Full Text] [Related]
4. Genotyping of cytochrome p450 isoform genes is useful for forensic identification of cadaver.
Ogawa K; Suno M; Shimizu K; Yoshida M; Awaya T; Matsubara K; Shiono H
Leg Med (Tokyo); 2003 Sep; 5(3):132-8. PubMed ID: 14568772
[TBL] [Abstract][Full Text] [Related]
5. CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South-East and East Asian populations: A systematic review.
Dorji PW; Tshering G; Na-Bangchang K
J Clin Pharm Ther; 2019 Aug; 44(4):508-524. PubMed ID: 30980418
[TBL] [Abstract][Full Text] [Related]
6. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
[TBL] [Abstract][Full Text] [Related]
7. CYP2C9, CYPC19 and CYP2D6 gene profiles and gene susceptibility to drug response and toxicity in Turkish population.
Arici M; Özhan G
Saudi Pharm J; 2017 Mar; 25(3):376-380. PubMed ID: 28344492
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.
Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A
Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetic relevant polymorphisms of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 in Bhutanese population.
Dorji PW; Wangchuk S; Boonprasert K; Tarasuk M; Na-Bangchang K
Drug Metab Pers Ther; 2019 Dec; 34(4):. PubMed ID: 32004143
[TBL] [Abstract][Full Text] [Related]
10. Relationships between CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 metabolic phenotypes and genotypes in a Nicaraguan Mestizo population.
de Andrés F; Altamirano-Tinoco C; Ramírez-Roa R; Montes-Mondragón CF; Dorado P; Peñas-Lledó EM; LLerena A
Pharmacogenomics J; 2021 Apr; 21(2):140-151. PubMed ID: 33024249
[TBL] [Abstract][Full Text] [Related]
11. CYP450 Genotype/Phenotype Concordance in Mexican Amerindian Indigenous Populations-Where to from Here for Global Precision Medicine?
de Andrés F; Sosa-Macías M; Ramos BPL; Naranjo MG; LLerena A
OMICS; 2017 Sep; 21(9):509-519. PubMed ID: 28873029
[TBL] [Abstract][Full Text] [Related]
12. Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus.
Semiz S; Dujic T; Ostanek B; Prnjavorac B; Bego T; Malenica M; Marc J; Causevic A
Bosn J Basic Med Sci; 2010 Nov; 10(4):287-91. PubMed ID: 21108610
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales.
Sistonen J; Fuselli S; Palo JU; Chauhan N; Padh H; Sajantila A
Pharmacogenet Genomics; 2009 Feb; 19(2):170-9. PubMed ID: 19151603
[TBL] [Abstract][Full Text] [Related]
14. Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics.
Naranjo MG; Rodrigues-Soares F; Peñas-Lledó EM; Tarazona-Santos E; Fariñas H; Rodeiro I; Terán E; Grazina M; Moya GE; López-López M; Sarmiento AP; Calzadilla LR; Ramírez-Roa R; Ortiz-López R; Estévez-Carrizo FE; Sosa-Macías M; Barrantes R; LLerena A;
OMICS; 2018 Sep; 22(9):575-588. PubMed ID: 30183544
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacogenetics and potential application in personalized medicine.
Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
[TBL] [Abstract][Full Text] [Related]
16. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population.
Halling J; Petersen MS; Damkier P; Nielsen F; Grandjean P; Weihe P; Lundgren S; Lundblad MS; Brøsen K
Eur J Clin Pharmacol; 2005 Aug; 61(7):491-7. PubMed ID: 16025294
[TBL] [Abstract][Full Text] [Related]
17. Genetic diversity of cytochrome P450 in patients receiving psychiatric care in Greece: a step towards clinical implementation.
Ragia G; Pallikarou M; Manolopoulou Y; Vorvolakos T; Manolopoulos VG
Pharmacogenomics; 2024 May; ():1-13. PubMed ID: 38884939
[TBL] [Abstract][Full Text] [Related]
18. Genetic Polymorphism of Drug-Metabolizing Enzymes CYP2C9 and CYP2C19 in Moroccan Population.
Afilal D; Basselam MA; Brakez Z; Chouham S; Brehm A; Izaabel EH
Genet Test Mol Biomarkers; 2017 May; 21(5):298-304. PubMed ID: 28282224
[TBL] [Abstract][Full Text] [Related]
19. Novel drug metabolism indices for pharmacogenetic functional status based on combinatory genotyping of CYP2C9, CYP2C19 and CYP2D6 genes.
Villagra D; Goethe J; Schwartz HI; Szarek B; Kocherla M; Gorowski K; Windemuth A; Ruaño G
Biomark Med; 2011 Aug; 5(4):427-38. PubMed ID: 21861665
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI).
Pachkoria K; Lucena MI; Ruiz-Cabello F; Crespo E; Cabello MR; Andrade RJ;
Br J Pharmacol; 2007 Mar; 150(6):808-15. PubMed ID: 17279092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
